IGF-1 LR3

What it is

IGF-1, insulin-like growth factor 1, is the worker behind growth hormone. Growth hormone gives the instruction; IGF-1 is produced mainly in the liver and carries it out in muscle, bone and other tissue: protein synthesis, cell division, repair. The name reveals the kinship with insulin, and that becomes important for the risks.

In the blood, IGF-1 is almost completely bound to binding proteins that shield it like bodyguards. Only a small fraction is free and active, and free IGF-1 is broken down quickly. The body thus doses its most powerful growth factor very cautiously. It is precisely this control that LR3 bypasses.

How the molecule is built

The variants were described in the early nineties. At position 3, an arginine sits in place of glutamic acid, the R3, and at the start hangs a short extension made from a piece of growth hormone, the Long. The result no longer fits the pattern of the binding proteins. The developers themselves wrote that the higher potency comes mainly from the weaker binding to these proteins and not from stronger binding at the receptor. In fact, LR3 even binds about 3 times worse to the IGF-1 receptor than the original.

It was intended as a tool for research. In cell cultures, the binding proteins that the cells release into the culture medium get in the way, because they capture normal IGF-1. A variant that cannot be captured works more reliably there. LR3 is still a standard additive in cell culture media today, including in biotech production. The bodybuilding scene simply helped itself from the lab shelf.

What is supposed to happen in muscle

Two mechanisms make IGF-1 so interesting for muscle building. First, hypertrophy: via the PI3K, Akt and mTOR signaling chain, existing muscle fibers become thicker. Second, IGF-1 activates satellite cells, the muscle’s stem cells, and can thus contribute to the formation of new fibers. Hence the scene’s hyperplasia myth.

In animals this is impressive. When young mice produced more IGF-1 in muscle themselves via a gene vector, muscle mass rose by 15 percent and strength by 14 percent; in old mice, strength was 27 percent above untreated muscles. That was, however, locally produced IGF-1, not injected LR3. In rats on cortisone, LR3 was about 2.5 times as effective as IGF-1, measured by weight and nitrogen balance.

What users report

LR3 is used almost exclusively in the experienced bodybuilding scene, mostly as a short-term tool in building phases. The fascination is fed by the animal data and by reports of rapid gains. The experienced users themselves stress that they eat carbohydrates with it and track blood glucose and IGF-1 in the lab, because hypoglycemia is said to be the most common beginner’s mistake. These are experience reports from a high-risk niche, not evidence of efficacy.

What the studies show

Francis 1992 — the blueprint

The research group produced the long IGF-1 variants and compared them with normal IGF-1 in muscle and liver cells. All variants were more potent than IGF-1, most of all the variant with arginine at position 3, and especially where the cells release binding proteins into the medium. From this follows the core of the molecule: it acts more strongly because it escapes the binding proteins.

Tomas 1992 — anabolic effect in rats

Male rats were given cortisone, which breaks down muscle, plus IGF-1 or variants via pumps, for 7 days. LR3 was about 2.5 times as potent as IGF-1 for weight and nitrogen balance, although it binds 3 times worse to the receptor. Under IGF-1, and especially under the variants, the gut became up to 45 percent heavier; the relative carcass weight remained low.

Conlon 1995 — organ growth

Female guinea pigs received a continuous infusion of IGF-1, IGF-2 or LR3 for 7 days. Under LR3, adrenal glands, gut, kidneys and spleen increased relative to body weight, but overall body growth did not. At the same time, LR3 lowered the body’s own IGF levels and the binding proteins. Organ growth has thus been demonstrated in animals, but not studied in humans.

Tomas 1997 — blood glucose

In marmosets and pigs, the blood glucose-lowering effect of IGF-1 and its variants was compared; LR3 was tested in pigs. The variants were 2 to 3 times more potent than IGF-1, and they kept blood glucose down much longer: over 4 hours, the reduction was about 4 to 8 times greater. This is the basis for the warning about hypoglycemia.

Where the data stop

The evidence pyramid stands on its head: clear cellular mechanisms, impressive animal data and nothing in humans. Controlled studies of LR3 in humans were not found, neither on muscle building nor on recovery nor on safety. Everything that circulates about the effect in humans is user reports. A recent review of peptides of the growth hormone axis accordingly places IGF-1 LR3 at the lowest level of evidence.

The hyperplasia idea has not been shown in humans either. The animal data on new fiber formation come mostly from locally produced IGF-1, not from injected LR3. And aging research supplies a counterargument: people in Ecuador with a defective growth hormone receptor and very low IGF-1 were followed for 22 years. They had only a single, non-fatal cancer and no diabetes, compared with 17 percent cancer and 5 percent diabetes in the comparison group. From a longevity perspective, permanently high IGF-1 is more likely the wrong direction.

Status, approval and legal

IGF-1 LR3 is not approved as a medicine in any country and is sold as a research reagent. WADA lists IGF-1 and its analogs among the prohibited growth factors, in and out of competition. LR3 can now be detected in blood by high-resolution mass spectrometry; its time as an undetectable agent is over. The approved counterpart is mecasermin, recombinant normal IGF-1, approved in the EU since 2007 for children and adolescents aged 2 to 18 with severe primary IGF-1 deficiency. Gray-market products range from genuine laboratory quality to questionable copies.

Safety

Three serious points arise from the pharmacology. First, hypoglycemia: IGF-1 is the cousin of insulin, and LR3 lowered blood glucose in animals more strongly and for longer than the original. Even with the approved mecasermin, hypoglycemia is among the most common side effects, in more than one in 10 of those treated. Second, the growth question: IGF-1 does not distinguish between muscle and everything else that wants to grow, and LR3 bypasses precisely the body’s own safeguards. Mecasermin must not be given in active or suspected neoplasia; for cancers, including past ones, there is no data basis for LR3. Third, organ growth, which has been shown in animals. A review also lists blood glucose derailments, fluid retention, muscle and joint pain and injection site reactions for the peptides of this axis. For pregnant and breastfeeding women, adolescents and people with diabetes it is all the more out of the question.

Sources

• Francis et al., J Mol Endocrinol 1992 (long IGF-1 variants)
• Tomas et al., Biochem J 1992 (anabolic effect in rats)
• Conlon et al., J Endocrinol 1995 (organ growth, guinea pigs)
• Tomas et al., J Endocrinol 1997 (blood glucose, pig and marmoset)
• Barton-Davis et al., PNAS 1998 (IGF-1 in muscle, mice)
• Guevara-Aguirre et al., Sci Transl Med 2011 (Laron cohort Ecuador; observation in humans with congenital IGF-1 deficiency, indirect – not a study of IGF-1 LR3)
• Dominikowski et al., Front Endocrinol 2026 (review of peptides of the GH-IGF-1 axis)
• Thomas et al., Anal Sci Adv 2022 (detection in doping tests)
• WADA, Prohibited List, section S2.3
• EMA, Increlex (mecasermin), EPAR